StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$26.42−1.33 (-4.79%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Zenas BioPharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Zenas BioPharma's revenue for the twelve months ending Dec 31, 2025 was $10.00M, up 100.0% year over year. For fiscal 2025 it was $10.00M, up 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.00M+100.0%
FY2024Dec 31, 2024$5.00M-90.0%
FY2023Dec 31, 2023$50.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$10.00M–
Q2 FY2026Jun 30, 2026$1.00M-90.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$10.00M–
Q4 FY2024Dec 31, 2024$5.00M-90.0%
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$50.00M–

More Zenas BioPharma figures

See a number that looks wrong?